

Revascularization of an Extensive Superficial Femoral Artery Chronic Total Occlusion and Associated Tibial Vessel Reconstruction

DANIELE SAVIO, MD
S.G. Bosco Hospital, Turin, Italy




Figure 1a




Figure 1b




Figure 1c

Figure 1d

CLINICAL CASE

The patient is a 68-year-old man with severe peripheral arterial disease. The patient presented with foot ulcerations and rest pain on the right side. Angiographic findings are demonstrated (Fig. 1a - 1d). He is a former smoker, having quit in 2005. He has hypertension and received anti-hypertensive drugs and aspirin 100 mg / day.

Arterial duplex showed obstructions of the superficial femoral artery (SFA), tibial trunk, and a tight stenosis of the posterior tibial artery with reduction of distal flow (maximum peak systolic velocity was 20 cm / s in the plantar arch).

PROCEDURE

The patient underwent angiography via a left femoral approach. The angiogram confirmed the duplex data of SFA chronic total occlusion (CTO), 25 cm in length, in the absence of a blind pouch (Fig. 1a). Additionally, angiography showed an unfavorable aortoiliac bifurcation, a tight stenosis of the main branch of the profunda femoris artery (Fig. 1b), an anterior tibial artery CTO, and a tight stenosis along the tibial trunk, peroneal artery and posterior tibial artery (Fig. 1c - 1d).

Previously the patient received percutaneous transluminal angioplasty (PTA) in the main branch of the profunda to rescue flow. Subsequently, after crossing the SFA CTO with a 0.035" GLIDEX straight tip guidewire and a vertebral 4 Fr GLIDEX catheter (Terumo Medical Corporation), two (6 mm x 150 mm) GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface were



Continued on back

PERFORMANCE
through experience



Figure 2a



Figure 2b

Figure 2c




Figure 2d

implanted in the SFA. To establish good run-off, simultaneous treatment of the tibial trunk, postostial peroneal artery and posterior tibial artery was performed with a kissing balloon technique two (2 mm x 120 mm AMPHIRION DEEP PTA balloons by Invatec).

RESULTS

Final angiography (Fig. 2a - 2d), demonstrates patency of the SFA, tibial trunk, peroneal, and posterior tibial arteries, without residual stenoses and improvement of distal run-off with excellent opacification of the plantar arch. The immediate duplex scan control showed a flow improvement with a distal posterior peak systolic velocity of 80 cm / s.

Patient received a dual antiplatelet regime for one month followed by a single anti-platelet regime thereafter. Six month duplex scan follow-up showed patency of all treated vessels.

PHYSICIAN COMMENTS

The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface offers the combination of flexibility and heparin-bonding technology particularly suitable for the treatment of chronic occlusions of the SFA and offers a good cost-benefit ratio, particularly for extensive obstructions. The device has excellent pushability through a narrow aortoiliac bifurcation. In cases such as this, the tibial vessel reconstruction is mandatory to warrant a durable primary patency.



W. L. GORE & ASSOCIATES, INC.

Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)

00800.6334.4673 (Europe)

800.437.8181 (United States)

928.779.2771 (United States)

goremedical.com

INDICATIONS FOR USE: The GORE® VIABAHN® Endoprosthesis is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery lesions with reference vessel diameters ranging from 4.0 – 7.5 mm. The GORE® VIABAHN® Endoprosthesis is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in iliac artery lesions with reference vessel diameters ranging from 4.0 – 12 mm. **CONTRAINDICATIONS:** The GORE® VIABAHN® Endoprosthesis is contraindicated for non-compliant lesions where full expansion of an angioplasty balloon catheter was not achieved during pre-dilatation, or where lesions cannot be dilated sufficiently to allow passage of the delivery system. Do not use the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface in patients with known hypersensitivity to heparin, including those patients who have had a previous incidence of Heparin-Induced Thrombocytopenia (HIT) type II. Refer to *Instructions for Use* at goremedical.com for a complete description of all warnings, precautions and adverse events. ^{Rx Only}

Products listed may not be available in all markets.

AMPHIRION DEEP is a trademark of Invatec. GLIDEX is a trademark of Terumo Medical Corporation.

GORE®, PERFORMANCE THROUGH EXPERIENCE, VIABAHN®, and designs are trademarks of W. L. Gore & Associates.

© 2010 W. L. Gore & Associates, Inc. AP0358-EN1 JULY 2010